DEFA14A: Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion, Expanding Rare Tumor Portfolio

Merck KGaA, Darmstadt, Germany, will acquire SpringWorks Therapeutics for $47 per share in cash, a deal valued at approximately $3.9 billion, to bolster its healthcare business and expand its presence in the rare tumor treatment market.

Summary

• Merck KGaA, Darmstadt, Germany, has entered into a definitive agreement to acquire SpringWorks Therapeutics for $47 per share in cash.
• The acquisition values SpringWorks at approximately $3.9 billion in equity value and $3.4 billion in enterprise value.
• The offer represents a 26% premium over SpringWorks' unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025.
• The acquisition is expected to immediately add revenue and accelerate midto long-term growth for Merck KGaA's Healthcare business.
• SpringWorks' portfolio includes OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLI (mirdametinib) for neurofibromatosis type 1-associated plexiform neurofibromas.
• The transaction is expected to close in the second half of 2025, pending shareholder and regulatory approvals.
• Merck KGaA plans to fund the acquisition with available cash and new debt.
• SpringWorks has a marketing authorization application under review with the European Medicines Agency (EMA) for nirogacestat, with a decision expected in Q2 2025.
• The marketing authorisation application for mirdametinib has been validated by the European Medicines Agency (EMA) with a potential approval in 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the acquisition, highlighting strategic benefits, financial accretion, and expanded market reach. The tone is optimistic, emphasizing the value creation for both companies and the potential to improve patient outcomes.

Positives

• The acquisition provides immediate revenue and accelerates long-term growth for Merck KGaA's Healthcare business.
• SpringWorks' portfolio complements Merck KGaA's existing efforts in rare tumors, such as pimicotinib for tenosynovial giant cell tumor (TGCT).
• The deal expands the reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide.
• SpringWorks' shareholders will receive a 26% premium over the unaffected 20-day volume-weighted average price as of February 7, 2025.
• SpringWorks employees will have new opportunities as part of a global organization.

Negatives

• The transaction is subject to shareholder and regulatory approvals, which could potentially delay or prevent the acquisition.
• Significant costs are associated with the proposed transaction.
• Potential litigation relating to the proposed transaction could arise.
• Restrictions during the pendency of the proposed transaction may impact SpringWorks' ability to pursue certain business opportunities.

Risks

• The occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement.
• Failure to satisfy closing conditions, including obtaining required regulatory approvals and SpringWorks stockholder approval.
• Disruptions from the proposed transaction and the impact of its announcement and pendency on SpringWorks' business.
• Effects of the proposed transaction on relationships with employees, business partners, or governmental entities.
• Response of competitors to the proposed transaction.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• Inability to consummate the proposed transaction in a timely manner or at all.
• Potential litigation relating to the proposed transaction.
• Restrictions during the pendency of the proposed transaction that may impact SpringWorks' ability to pursue certain business opportunities.
• Risks related to the advancement of product candidates into, and successful completion of, preclinical studies and clinical trials.
• Risks and uncertainties related to regulatory application, review and approval processes and SpringWorks' compliance with applicable legal and regulatory requirements.
• General industry conditions and competition.
• General economic factors.

Future Outlook

The acquisition is expected to immediately contribute to Merck KGaA, Darmstadt, Germany's revenues and is expected to be accretive to Merck KGaA, Darmstadt, Germany's earnings per share pre (EPS pre) in 2027. Merck KGaA, Darmstadt, Germany will retain the ability to pursue larger transactions and continue to evaluate opportunities across its three sectors, with Life Science a priority.

Management Comments

• Beln Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany, stated that the acquisition is a major step in their active portfolio strategy and sharpens the focus on rare tumors, accelerates growth, and strengthens their presence in the U.S.
• Peter Guenter, member of the Executive Board and CEO of Healthcare at Merck KGaA, Darmstadt, Germany, said that the combination of Merck KGaA, Darmstadt, Germany and SpringWorks is perfect to improve outcomes for patients with rare tumors and build a strong foundation for further investments in this area.
• Saqib Islam, CEO of SpringWorks Therapeutics, stated that joining forces with Merck KGaA, Darmstadt, Germany will create significant value for stakeholders and leverage their resources and expertise to build a brighter future for patient communities.

Industry Context

This acquisition reflects a broader trend in the pharmaceutical industry of larger companies acquiring smaller, innovative firms to expand their pipelines and market presence, particularly in specialized areas like rare diseases and oncology. Merck KGaA's move to acquire SpringWorks is consistent with its strategy to focus on high-growth areas and strengthen its position in the U.S. market.

Comparison to Industry Standards

• The acquisition price of $3.9 billion is comparable to other recent deals in the biopharmaceutical industry focused on rare diseases and oncology assets.
• For example, Pfizer's acquisition of Global Blood Therapeutics for $5.4 billion in 2022 and Sanofi's acquisition of Kadmon Holdings for $1.9 billion in 2021 are similar in terms of strategic focus and deal size.
• The 26% premium offered by Merck KGaA is within the typical range for acquisitions in the pharmaceutical sector, which often see premiums of 20-40% depending on the target company's growth prospects and pipeline value.
• The expected accretion to Merck KGaA's EPS in 2027 is a common benchmark for evaluating the financial impact of acquisitions in the pharmaceutical industry, with companies often targeting accretion within 3-5 years of closing.

Stakeholder Impact

• SpringWorks' shareholders are expected to benefit from the 26% premium offered by Merck KGaA.
• Patients with rare tumors are expected to benefit from the expanded reach of SpringWorks' therapies and Merck KGaA's resources.
• SpringWorks' employees are expected to have new opportunities as part of a global organization.
• Merck KGaA's shareholders are expected to benefit from the accretive nature of the acquisition and the strengthened Healthcare business.

Next Steps

• SpringWorks will file a proxy statement with the SEC relating to a special meeting of its stockholders.
• SpringWorks will hold a special meeting of its stockholders to vote on the adoption of the merger agreement.
• The parties will seek required regulatory approvals.
• The transaction is expected to close in the second half of 2025, subject to the satisfaction of customary closing conditions.

Key Dates

Keywords

acquisition, SpringWorks Therapeutics, Merck KGaA, rare tumors, nirogacestat, mirdametinib, pharmaceutical, healthcare, merger, oncology